Bioresorbable scaffolds in lower limb arterial disease: a narrative review of advancements and future directions

Abstract

Endovascular recanalization has revolutionized the treatment of peripheral artery disease (PAD), offering minimally invasive alternatives to open surgery. However, permanent metallic stents, while effective in restoring blood flow, are associated with long-term complications such as chronic inflammation, restenosis, and stent thrombosis. Bioresorbable scaffolds (BRS) have emerged as an innovative solution, providing temporary mechanical support while delivering antiproliferative drugs before fully degrading, thus eliminating the risks associated with permanent implants. Significant advancements in bioresorbable materials have led to the development of new-generation scaffolds with improved radial strength, controlled degradation rates, and enhanced drug-eluting properties. Several BRS platforms, including polymer- and magnesium-based designs, are undergoing clinical and preclinical evaluation for peripheral applications. Early trials suggest that BRS may offer comparable short-term patency rates to conventional stents while potentially reducing late adverse events. However, challenges such as scaffold thrombosis, mechanical integrity in large and calcified vessels, and long-term efficacy remain under investigation. This narrative review explores the evolution of BRS technology, the mechanisms of scaffold resorption, current clinical evidence, and future prospects for their use in peripheral endovascular interventions. As research progresses, BRS may represent a paradigm shift in the treatment of PAD, offering a balance between structural support and vascular restoration.

Keywords

Bioresorbable scaffolds / peripheral artery disease / endovascular recanalization / drug-eluting stents

References

[1] Song P,Fang Z,Wang H.et al. Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study Lancet Glob Health. 2020 8 e721 9

[2] Lovell M, Harris K, Forbes T, et al.; Peripheral Arterial Disease Coalition. Peripheral arterial disease: lack of awareness in Canada Can J Cardiol. 2009 25 39 45

[3] Criqui MH, Matsushita K, Aboyans V, et al.; American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Lifestyle and Cardiometabolic Health; Council on Peripheral Vascular Disease; and Stroke Council. Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association Circulation. 2021 144 e171 91

[4] Johnston LE,Stewart BT,Yangni-Angate H.et al. Peripheral arterial disease in Sub-Saharan Africa: a review JAMA Surg. 2016 151 564 72

[5] Aronow WS. Peripheral arterial disease of the lower extremities Arch Med Sci. 2012 8 375 88 PMC3361053

[6] Salameh MJ,Rundek T,Boden-Albala B.et al. Self-reported peripheral arterial disease predicts future vascular events in a community-based cohort J Gen Intern Med. 2008 23 1423 8 PMC2518027

[7] Pérez Mejias EL,Faxas SM,Taveras NT.et al. Peripheral artery disease as a risk factor for myocardial infarction Cureus. 2021 13 e15655 PMC8280959

[8] McDermott MM. Functional impairment in peripheral artery disease and how to improve it in 2013 Curr Cardiol Rep. 2013 15 347 PMC3683561

[9] Normahani P,Mustafa C,Shalhoub J.et al. A systematic review and meta-analysis of the diagnostic accuracy of point-of-care tests used to establish the presence of peripheral arterial disease in people with diabetes J Vasc Surg. 2021 73 1811 20

[10] Voelker R. Reforms needed in adolescent health care JAMA. 2009 301 368

[11] Hwang JH,Hwang JH,Lee SY,Lee J. Prostatic abscess caused by klebsiella pneumoniae: a 6-year single-center study J Clin Med. 2022 11 PMC9099488

[12] Erzinger FL,Polimanti AC,Pinto DM.et al. Brazilian Society of Angiology and Vascular Surgery guidelines on peripheral artery disease J Vasc Bras. 2024 23 e20230059

[13] Törngren K,Eriksson S,Arvidsson J.et al. A reperfusion BOLD-MRI Tissue perfusion protocol reliably differentiate patients with peripheral arterial occlusive disease from healthy controls J Clin Med. 2021 10 3643 PMC8397020

[14] Xu J,Chung JJ,Jin T. Chemical exchange saturation transfer imaging of creatine, phosphocreatine, and protein arginine residue in tissues NMR Biomed. 2023 36 e4671 PMC9250548

[15] Sporkin HL,Patel TR,Betz Y.et al. Chemical exchange saturation transfer magnetic resonance imaging identifies abnormal calf muscle-specific energetics in peripheral artery disease Circ Cardiovasc Imaging. 2022 15 e013869

[16] Conte MS, Pomposelli FB, Clair DG, et al.; Society for Vascular Surgery Lower Extremity Guidelines Writing Group, Society for Vascular Surgery. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication J Vasc Surg. 2015 61 Suppl 2S 41S

[17] Kim TI,Zhang Y,Cardella JA,Guzman RJ,Ochoa Chaar CI. Outcomes of bypass and endovascular interventions for advanced femoropopliteal disease in patients with premature peripheral artery disease J Vasc Surg. 2021 74 1968 1977.e3

[18] Zhou Y,Zhang Z,Lin S.et al. Comparative efficacy and safety of endovascular treatment modalities for femoropopliteal artery lesions: a network meta-analysis of randomized controlled trials Cardiovasc Intervent Radiol. 2020 43 204 14

[19] Brodmann M,Wissgott C,Holden A.et al. Treatment of infrapopliteal post-PTA dissection with tack implants: 12-month results from the TOBA-BTK study Catheter Cardiovasc Interv. 2018 92 96 105 PMC6099281

[20] Laird JR. Limitations of percutaneous transluminal angioplasty and stenting for the treatment of disease of the superficial femoral and popliteal arteries J Endovasc Ther. 2006 13 Suppl 2 II30 40

[21] Meraj PM,Jauhar R,Singh A. Bare metal stents versus drug eluting stents: where do we stand in 2015? Curr Treat Options Cardiovasc Med. 2015 17 393

[22] Clare J,Ganly J,Bursill CA,Sumer H,Kingshott P,de Haan JB. The mechanisms of restenosis and relevance to next generation stent design Biomolecules. 2022 12 430 PMC8945897

[23] Dinc R. A review of the current state in neointimal hyperplasia development following endovascular intervention and minor emphasis on new horizons in immunotherapy Transl Clin Pharmacol. 2023 31 191 201 PMC10772059

[24] Lepor NE. Primary prevention, treatment, and secondary prevention of late and very late stent thrombosis Rev Cardiovasc Med 2007 8 Suppl 1 S27 33

[25] Liu J,Li T,Huang W.et al. Drug-coated balloons used in peripheral artery disease: experience from a single center J Int Med Res. 2020 48 300060520940157 PMC7416143

[26] Cui HJ,Wu YF. The efficacy of drug-coated balloons and drug-eluting stents in infrapopliteal revascularization: a meta-analysis J Endovasc Ther. 2025 32 1799 820

[27] Tataru DA,Lazar FL,Onea HL.et al. Benefits and challenges of drug-coated balloons in peripheral artery disease: from molecular mechanisms to clinical practice Int J Mol Sci. 2024 25 8749 PMC11354615

[28] Ogata K,Nishihira K,Asano Y.et al. Clinical comparison of drug-coated balloon and drug-eluting stent for femoropopliteal lesions in chronic limb-threatening ischemia with wounds Circ J. 2024 88 1647 55

[29] Chang GH,Azar DA,Lyle C,Chitalia VC,Shazly T,Kolachalama VB. Intrinsic coating morphology modulates acute drug transfer in drug-coated balloon therapy Sci Rep. 2019 9 6839 PMC6497887

[30] Stratakos E,Antonini L,Poletti G.et al. Investigating balloon-vessel contact pressure patterns in angioplasty: in silico insights for drug-coated balloons Ann Biomed Eng. 2023 51 2908 22 PMC10632265

[31] Bonaventura K,Schwefer M,Yusof AKM.et al. Systematic scoring balloon lesion preparation for drug-coated balloon angioplasty in clinical routine: results of the PASSWORD observational study Adv Ther. 2020 37 2210 23 PMC7467461

[32] Giannopoulos S,Ghanian S,Parikh SA,Secemsky EA,Schneider PA,Armstrong EJ. Safety and efficacy of drug-coated balloon angioplasty for the treatment of chronic limb-threatening ischemia: a systematic review and meta-analysis J Endovasc Ther. 2020 27 647 57

[33] Zilinyi RS,Alsaloum M,Snyder DJ.et al. Surgical and endovascular therapies for below-the-knee peripheral arterial disease: a contemporary review J Soc Cardiovasc Angiogr Interv. 2024 3 101268 PMC11308828

[34] Iqbal J,Onuma Y,Ormiston J,Abizaid A,Waksman R,Serruys P. Bioresorbable scaffolds: rationale, current status, challenges, and future Eur Heart J. 2014 35 765 76

[35] Kazuki Y,Kobayashi K,Hirabayashi M.et al. Humanized UGT2 and CYP3A transchromosomic rats for improved prediction of human drug metabolism Proc Natl Acad Sci U S A. 2019 116 3072 81 PMC6386724

[36] Jinnouchi H,Virmani R,Finn AV. Long-term vasomotion after absorb: fact or fiction? JACC Cardiovasc Interv. 2018;11:1572-5

[37] Shen Y,Yu X,Cui J.et al. Development of biodegradable polymeric stents for the treatment of cardiovascular diseases Biomolecules. 2022 12 1245 PMC9496387

[38] Hu T,Yang C,Lin S,Yu Q,Wang G. Biodegradable stents for coronary artery disease treatment: Recent advances and future perspectives Mater Sci Eng C Mater Biol Appl. 2018 91 163 78

[39] Diletti R,Serruys PW,Farooq V.et al. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: Rationale and study design Am Heart J. 2012 164 654 63

[40] Kereiakes DJ, Ellis SG, Metzger DC, et al.; ABSORB III Investigators. Clinical outcomes before and after complete everolimus-eluting bioresorbable scaffold resorption: five-year follow-up from the ABSORB III trial Circulation. 2019 140 1895 903

[41] Tesfamariam B. Bioresorbable vascular scaffolds: biodegradation, drug delivery and vascular remodeling Pharmacol Res. 2016 107 163 71

[42] Mostaed E,Sikora-Jasinska M,Drelich JW,Vedani M. Zinc-based alloys for degradable vascular stent applications Acta Biomater. 2018 71 1 23 PMC5927626

[43] Stone GW,Kimura T,Gao R.et al. Time-varying outcomes with the absorb bioresorbable vascular scaffold during 5-year follow-up: a systematic meta-analysis and individual patient data pooled study JAMA Cardiol. 2019 4 1261 9 PMC6777269

[44] Waksman R. Current state of the absorbable metallic (magnesium) stent EuroIntervention. 2009 5 Suppl F F94 7

[45] Barkholt TØ, Webber B, Holm NR, Ormiston JA. Mechanical properties of the drug-eluting bioresorbable magnesium scaffold compared with polymeric scaffolds and a permanent metallic drug-eluting stent Catheter Cardiovasc Interv. 2020 96 E674 82 PMC7754471

[46] IBS Titan^TM peripheral scaffold. Available from https://www.biotyxmed.com/en_ggjt.html [accessed 3 March 2026].

[47] MeRes100^TM Brochure. Available from https://storage.e.jimdo.com/file/d4a3bcc8-af71-49d6-bf6f-90cb65f9681c/meres100-bioresorbable-scaffolds-brs-1617184336pdf.pdf [accessed 3 March 2026].

[48] Lee JM, Joh HS, Choi KH, et al.; SMART-REWARD Investigators. Safety and efficacy of everolimus-eluting bioresorbable vascular scaffold versus second-generation drug-eluting stents in real-world practice J Korean Med Sci. 2023 38 e34 PMC9902667

[49] Gao Z,Jiang W,Ran F. Peripheral vascular bioresorbable scaffolds: past, present, and future Medicine Plus. 2024 1 100031

[50] Bosiers MJ,Rand T,Uberoi R.et al. MOTIV bioresorbable scaffold in below-the-knee artery disease: European post-market pilot BTK trial: 36-month results Cardiovasc Intervent Radiol. 2025 48 1576 86 PMC12572035

[51] Brodmann M,Falah B,Palena LM.et al. Clinical and angiographic outcomes of a novel thin strut Poly(L-lactide) based bioresorbable vascular scaffold in below knee arterial disease: the RESOLV I first in human study. Eur J Vasc Endovasc Surg. 2025

[52] Seguchi M,Aytekin A,Xhepa E.et al. Vascular response following implantation of the third-generation drug-eluting resorbable coronary magnesium scaffold: an intravascular imaging analysis of the BIOMAG-I first-in-human study EuroIntervention. 2024 20 e1173 83

[53] Charpentier E,Barna A,Guillevin L,Juliard JM. Fully bioresorbable drug-eluting coronary scaffolds: a review Arch Cardiovasc Dis. 2015 108 385 97

[54] Green MR,Couchman JR. Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition J Invest Dermatol. 1985 85 239 45

[55] Pradhan A,Vishwakarma P,Vankar S,Sethi R. “The unpredictable ABSORB” - very late stent thrombosis of bioresorbable vascular scaffold Heart Views. 2019 20 65 9 PMC6686611

[56] Serruys PW,Katagiri Y,Sotomi Y.et al. Arterial remodeling after bioresorbable scaffolds and metallic stents J Am Coll Cardiol. 2017 70 60 74

[57] Koppula AV,Raja MS,Ahmad M. Can HbA_1c levels be used as a prognostic tool for patients undergoing coronary interventions? JACC Cardiovasc Interv. 2021 14 1159

[58] Giacchi G,Ortega-Paz L,Brugaletta S,Ishida K,Sabaté M. Bioresorbable vascular scaffolds technology: current use and future developments Med Devices. 2016 9 185 98 PMC4946828

[59] Jiang M,Zhang Y,Han Y,Yuan X,Gao L. Neoatherosclerosis: a distinctive pathological mechanism of stent failure Rev Cardiovasc Med. 2024 25 95 PMC11263888

[60] Brugaletta S,Heo JH,Garcia-Garcia HM.et al. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? Eur Heart J. 2012 33 1325 33

[61] Gomez-Lara J,Brugaletta S,Ortega-Paz L.et al. Long-term coronary functional assessment of the infarct-related artery treated with everolimus-eluting bioresorbable scaffolds or everolimus-eluting metallic stents: insights of the TROFI II trial JACC Cardiovasc Interv. 2018 11 1559 71

[62] Ortega-Paz L,Capodanno D,Gori T.et al. Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score EuroIntervention. 2017 12 2110 7

[63] Farhan M,Hasan G,Sobhi A.et al. Bioresorbable scaffolds advances, challenges, and future directions Ann Med Surg. 2025 87 4173 83

[64] Cheng Y,Ferrone M,Wang Q.et al. Impact of coronary atherosclerosis on bioresorbable vascular scaffold resorption and vessel wall integration JACC Basic Transl Sci. 2020 5 619 29 PMC7315185

[65] El Khoury R,Tzvetanov I,Estrada EA.et al. Drug-eluting, balloon-expandable, bioresorbable vascular scaffolds reduce neointimal thickness and stenosis in an animal model of percutaneous peripheral intervention JVS Vasc Sci. 2023 4 100114 PMC10403740

[66] Vahl TP,Gasior P,Gongora CA.et al. Four-year polymer biocompatibility and vascular healing profile of a novel ultrahigh molecular weight amorphous PLLA bioresorbable vascular scaffold: an OCT study in healthy porcine coronary arteries EuroIntervention. 2016 12 1510 8

[67] Torii S,Yamamoto A,Yoshikawa A.et al. Degradation of a novel magnesium alloy-based bioresorbable coronary scaffold in a swine coronary artery model Cardiovasc Interv Ther. 2024 39 428 37 PMC11436393

[68] Kumar S,Malviya R,Sridhar SB. Bioresorbable polymeric scaffold: advancing minimally invasive surgical procedure for cardiovascular and its applications. In: Malviya R, Sundram S, Editors. Sustainable nanocomposites with green biomaterials. Springer Nature Switzerland: Cham; 2025; pp. 61-82.

[69] Lipinski MJ,Acampado E,Cheng Q.et al. Comparison of acute thrombogenicity for magnesium versus stainless steel stents in a porcine arteriovenous shunt model EuroIntervention. 2019 14 1420 7

[70] Waksman R,Lipinski MJ,Acampado E.et al. Comparison of acute thrombogenicity for metallic and polymeric bioabsorbable scaffolds: magmaris versus absorb in a porcine arteriovenous shunt model Circ Cardiovasc Interv. 2017 10

[71] Warren BE,Tan KT,Rajan DK.et al. Moving away from metal: step toward the future with bioresorbable vascular scaffolds and novel antiproliferative agents JVS Vasc Sci. 2025 6 100277 PMC11791325

[72] Kum S,Ipema J,Chun-Yin DH.et al. Early and midterm experience with the absorb everolimus-eluting bioresorbable vascular scaffold in Asian patients with chronic limb-threatening ischemia: one-year clinical and imaging outcomes from the DISAPEAR registry J Endovasc Ther. 2020 27 616 22

[73] Varcoe RL,Schouten O,Thomas SD,Lennox AF. Experience with the absorb everolimus-eluting bioresorbable vascular scaffold in arteries below the knee: 12-month clinical and imaging outcomes JACC Cardiovasc Interv. 2016 9 1721 8

[74] Varcoe RL,Parikh SA,DeRubertis BG.et al. Evaluation of an infrapopliteal drug-eluting resorbable scaffold: design methodology for the LIFE-BTK randomized controlled trial J Soc Cardiovasc Angiogr Interv. 2023 2 100964 PMC11307544

[75] R3 Vascular Inc. Bioresorbable Sirolimus-eluting scaffold treatment for below the knee disease (ELITE-BTK). Available from https://clinicaltrials.gov/study/NCT06071429 [accessed 3 March 2026].

[76] Drug impregnated bioabsorbable stent in asian population extremity arterial revascularization (DISAPEAR Study) (DISAPEAR). Available from https://clinicaltrials.gov/study/NCT02043795 [accessed 3 March 2026].

[77] LIFE-BTK Randomized Controlled Trial (LIFE-BTK). Available from https://clinicaltrials.gov/study/NCT04227899 [accessed 3 March 2026].

[78] R3 Vascular Inc. Study of the R3 Vascular Drug-Eluting Bioresorbable Scaffold in Treating Below the Knee Arterial Disease (RESOLV I). Available from https://clinicaltrials.gov/study/NCT04912323 [accessed 3 March 2026].

[79] MOTIV BTK randomized controlled trial. Available from https://clinicaltrials.gov/study/NCT05406622 [accessed 3 March 2026].

[80] Abbott Vascular. The ABSORB bioresorbable scaffold below the knee (BTK) study. Available from https://clinicaltrials.gov/study/NCT02793349 [accessed 3 March 2026].

[81] Peng X,Qu W,Jia Y,Wang Y,Yu B,Tian J. Bioresorbable scaffolds: contemporary status and future directions Front Cardiovasc Med. 2020 7 589571 PMC7733966

[82] Martinelli O,Alunno A,Drudi FM,Malaj A,Irace L. Duplex ultrasound versus CT angiography for the treatment planning of lower-limb arterial disease J Ultrasound. 2021 24 471 9 PMC8572174

[83] Demola P,Meucci F,Stolcova M,Mario CD,Mattesini A. The DESolve^® novolimus bioresorbable scaffold Future Cardiol. 2021 17 945 51

[84] Abizaid A,Kedev S,Ali RBM.et al. Imaging and 2-year clinical outcomes of thin strut sirolimus-eluting bioresorbable vascular scaffold: the MeRes-1 extend trial Catheter Cardiovasc Interv. 2021 98 1102 10

[85] Song L, Xu B, Chen Y, et al.; FUTURE-II Trial Investigators. Thinner strut sirolimus-eluting BRS versus EES in patients with coronary artery disease: FUTURE-II trial JACC Cardiovasc Interv. 2021 14 1450 62

[86] Jiménez JM,Davies PF. Hemodynamically driven stent strut design Ann Biomed Eng. 2009 37 1483 94 PMC2819751

[87] van Zandvoort LJC,Dudek D,Weber-Albers J.et al. Intravascular ultrasound findings of the Fantom sirolimus-eluting bioresorbable scaffold at six- and nine-month follow-up: the FANTOM II study EuroIntervention. 2018 14 e1215 23

[88] Fan W,Tan J,Li L.et al. Efficacy and safety of absorb everolimus-eluting bioresorbable vascular scaffold in peripheral artery disease: a single-arm meta-analysis J Endovasc Ther. 2023 30 651 63

[89] Beckman JA,Schneider PA,Conte MS. Advances in revascularization for peripheral artery disease: revascularization in PAD Circ Res. 2021 128 1885 912

[90] Zhao N,Zhu D. Endothelial responses of magnesium and other alloying elements in magnesium-based stent materials Metallomics. 2015 7 118 28 PMC4873155

[91] Saberi A,Bakhsheshi-rad HR,Abazari S.et al. A comprehensive review on surface modifications of biodegradable magnesium-based implant alloy: polymer coatings opportunities and challenges Coatings. 2021 11 747

[92] Leone A,Simonetti F,Avvedimento M.et al. Ultrathin struts drug-eluting stents: a state-of-the-art review J Pers Med. 2022 12 1378 PMC9503315

[93] Haude M,Wlodarczak A,van der Schaaf RJ.et al. A new resorbable magnesium scaffold for de novo coronary lesions (DREAMS 3): one-year results of the BIOMAG-I first-in-human study EuroIntervention. 2023 19 e414 22

[94] Menze R,Hesse B,Kusmierczuk M.et al. Synchrotron microtomography reveals insights into the degradation kinetics of bio-degradable coronary magnesium scaffolds Bioact Mater. 2024 32 1 11 PMC10522944

[95] Kang SH,Gogas BD,Jeon KH.et al. Long-term safety of bioresorbable scaffolds: insights from a network meta-analysis including 91 trials EuroIntervention. 2018 13 1904 13

[96] Early M,Kelly DJ. The consequences of the mechanical environment of peripheral arteries for nitinol stenting Med Biol Eng Comput. 2011 49 1279 88

[97] Struczewska P,Razian SA,Townsend K.et al. Mechanical, structural, and physiologic differences between above and below-knee human arteries Acta Biomater. 2024 177 278 99 PMC11456514

[98] Sakamoto A,Jinnouchi H,Torii S,Virmani R,Finn AV. Understanding the impact of stent and scaffold material and strut design on coronary artery thrombosis from the basic and clinical points of view Bioengineering. 2018 5 71 PMC6164756

[99] Nguyen DT,Smith AF,Jiménez JM. Stent strut streamlining and thickness reduction promote endothelialization J R Soc Interface. 2021 18 20210023 PMC8371379

[100] Marsden Back L,Gentry-Maharaj A,Ladwiniec A. The safety and efficacy profile of magnesium-based bioresorbable coronary stents as compared to poly-L-lactic acid-based bioresorbable and contemporary drug-eluting coronary stents-a systematic review Cardiol Res Pract. 2025 2025 7481956 PMC12457060

[101] Cheng CK,Wang N,Wang L,Huang Y. Biophysical and biochemical roles of shear stress on endothelium: a revisit and new insights Circ Res. 2025 136 752 72 PMC11949231

[102] Kawashima H,Ono M,Kogame N.et al. Drug-eluting bioresorbable scaffolds in cardiovascular disease, peripheral artery and gastrointestinal fields: a clinical update Expert Opin Drug Deliv. 2020 17 931 45

[103] Azzalini L,Ellis SG,Kereiakes DJ.et al. Optimal dual antiplatelet therapy duration for bioresorbable scaffolds: an individual patient data pooled analysis of the ABSORB trials EuroIntervention. 2021 17 e981 8

[104] Wu Y,Yin J,Li C.et al. The standard versus prolonged dual antiplatelet therapy after the XINSORB bioresorbable scaffold implantation (SPARTA) trial: study protocol for a randomized controlled trial Trials. 2023 24 49 PMC9854195

[105] Angiolillo DJ,Galli M,Alexopoulos D.et al. International consensus statement on platelet function and genetic testing in percutaneous coronary intervention: 2024 update JACC Cardiovasc Interv. 2024 17 2639 63

[106] O’Riordan M. The bioresorbable stent story so far: what promise? What price? Available from https://www.tctmd.com/news/bioresorbable-stent-story-so-far-what-promise-what-price [accessed 3 March 2026].

[107] Baron SJ, Lei Y, Chinnakondepalli K, et al.; ABSORB III Investigators. Economic outcomes of bioresorbable vascular scaffolds versus everolimus-eluting stents in patients undergoing percutaneous coronary intervention: 1-year results from the ABSORB III trial JACC Cardiovasc Interv. 2017 10 774 82

[108] Kozuma K, Tanabe K, Hamazaki Y, et al.; ABSORB Japan Investigators. Long-term outcomes of absorb bioresorbable vascular scaffold vs. everolimus-eluting metallic stent- a randomized comparison through 5 years in Japan Circ J. 2020 84 733 41

[109] Europe Bioresorbable Vascular Scaffold Market Worth $103.45 Million By 2030. Available from https://www.grandviewresearch.com/press-release/europe-bioresorbable-vascular-scaffold-market-analysis [accessed 3 March 2026].

[110] McKeown LA. Bioresorbable scaffold for CLTI appears to be an economical option: LIFE-BTK. Available from https://www.tctmd.com/news/bioresorbable-scaffold-clti-appears-be-economical-option-life-btk [accessed 3 March 2026].

[111] Wlodarczak A,Montorsi P,Torzewski J.et al. One- and two-year clinical outcomes of treatment with resorbable magnesium scaffolds for coronary artery disease: the prospective, international, multicentre BIOSOLVE-IV registry EuroIntervention. 2023 19 232 9

[112] Felix C. Absorb bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease in clinical practice. 2019. https://repub.eur.nl/pub/116450/ [accessed 3 March 2026].

[113] Koh DJ,Tao BS,Alonso A.et al. Regional and specialty-based medicare reimbursement trends in arterial endovascular procedures J Vasc Surg. 2025 82 1503 1510.e1

[114] Schmid T. Costs of treating cardiovascular events in Germany: a systematic literature review Health Econ Rev. 2015 5 27

[115] Wang Y,Zhang X. Vascular restoration therapy and bioresorbable vascular scaffold Regen Biomater. 2014 1 49 55 PMC4669005

[116] Gaudiello E,Melly L,Cerino G.et al. Scaffold composition determines the angiogenic outcome of cell-based vascular endothelial growth factor expression by modulating its microenvironmental distribution Adv Healthc Mater. 2017 6 1700600

[117] Chu TM,Chan YC,Cheng SW. Evidence for treating peripheral arterial diseases with biodegradable scaffolds J Cardiovasc Surg. 2017 58 87 94

[118] Tomilova OG,Kryukov VY,Kryukova NA.et al. Effects of passages through an insect or a plant on virulence and physiological properties of the fungus Metarhizium robertsii PeerJ. 2023 11 e15726 PMC10424674

[119] Gordon LG,Rodriguez-Acevedo AJ,Køster B.et al. Association of indoor tanning regulations with health and economic outcomes in North America and Europe JAMA Dermatol. 2020 156 401 10 PMC7042819

[120] Helou B,Bel-Brunon A,Dupont C.et al. Patient-specific finite element simulation of peripheral artery percutaneous transluminal angioplasty to evaluate the procedure outcome without stent implantation Int J Numer Method Biomed Eng. 2023 39 e3685

[121] Noble C,Carlson KD,Neumann E.et al. Evaluation of the role of peripheral artery plaque geometry and composition on stent performance J Mech Behav Biomed Mater. 2021 116 104346 PMC7933123